
Evidence-Based Oncology:FUTURE OF INCENTIVE-DRIVEN PATHWAY ADHERENCE

A SYNDICATED STUDY



HRA®'s Oncology Pathways: Future of Incentive-Driven Adherence explores decisions by payers to provide financial incentives to oncologists to follow evidence-based treatment pathways. This creates an opportunity for pharmaceutical companies to understand the implications on current brand utilization and future prescribing trends.

RESEARCH TOPICS:

- Key attributes driving decision making among payers about the perceived value of clinical pathways to patients and on cost of care
- Market forces driving the use of clinical pathways in oncology

ROBUST METHODOLOGY:



Phase 1

Extensive Literature Search



Phase 2
Qualitative Research



Phase 3

Quantitative Research

CONTACT US

To discuss how HRA® can provide insights to support your organization's strategic initiatives:





HARA DATA DRIVEN INTELLIGENCE



Applications:

- Understand how pathways are developed and the roles of oncologists, payers, and third-party vendors
- Map out goals for providers to follow clinical pathways
- Gauge the receptivity of oncologists to the use of clinical pathways and the impact of incentives
- Determine the impact of clinical pathways on patient care and implications for manufacturers

Highlights:

- The use of clinical pathways has been driven by both payers and oncologists as payers strive to reduce costs and oncologists look to improve patient outcomes
- Pathways not only provide consensus on the best treatments, but will collect comparative effectiveness data
- Pathway development is expected to expand to include the less-common tumor types, providing manufacturers the opportunity to open a dialogue with pathway vendors and decision makers to help ensure an on-pathway position

Deliverables:

- Final report integrating results from all phases
- Executive summary with conclusions and implications
- Detailed findings, supported by charts/graphs and verbatim quotes where appropriate